PTGX · Protagonist Therapeutics, Inc
$154.94
-2.40 (-1.53%)
At close · Aug 19
Market Cap
$10.25B
Shares
64.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$154.94
Open$160.81
Day$154.22–160.81
52W close$56.04–158.62
Avg vol 30d588K
Short int7.5M · 11.7% float · 14.2d
Short vol48%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Mar 21, 2027
Est · unconfirmed
· in 30 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+52%
above
Price vs 50-day avg
+17%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
96%
near high
Momentum
relative strength
1-month return
+14%
trailing
6-month return
+75%
trailing
YTD return
+77%
this year
Relative strength
+64%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $132 › 200d $102 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +61 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.66% of float · ▼ -9.0% MoM · 14.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
344 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
−89%
Y/Y
EPS growth
−148%
Y/Y
Free cash flow
$56.1M
Valuation
P/E 153.8
rich
Balance sheet
$118.6M
net cash
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−16%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+52%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
96%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $132 › 200d $102 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +61 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.66% of float · ▼ -9.0% MoM · 14.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
344 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $56
Now $155 · 96%
Range high $159
vs 200-day avg +52%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTGX
this stock
Protagonist Therapeutics, Inc
|
$10.25B | +77.4% | -89.4% | 153.8 | 11.7% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTGX | +1.9% | +14.4% | +75.3% | +13.4% | +77.4% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +2.4% | +11.5% | +63.7% | +10.4% | +64.6% |
Key facts
CIK
1377121
CUSIP
74366E102
13F (30d)
325 filings
316 filers
Visit website
Investor relations